I am a reproductive‑age woman taking letrozole 7.5 mg from cycle day 3 to 7; my follicle‑stimulating hormone (FSH) rose to 12.2 IU/L on day 7 and fell to 2.4 IU/L on day 9, and this evening (cycle day 9 at 11 pm) I have mild lower‑abdominal cramping, a small amount of cervical mucus and light spotting—are these findings normal and what should I do?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cycle Day 9 Cramping and Spotting During Letrozole Treatment

Your symptoms of mild cramping, cervical mucus, and light spotting on cycle day 9 are expected physiologic responses to letrozole-induced ovarian stimulation and do not indicate a problem. The dramatic FSH fluctuation you describe (12.2 IU/L on day 7 dropping to 2.4 IU/L on day 9) reflects normal negative feedback as your follicles mature and produce estrogen, which is precisely how letrozole works 1.

Understanding Your Symptoms

These findings are entirely normal for this stage of your cycle:

  • Cramping on cycle day 9 represents follicular growth and stretching of the ovarian capsule as your dominant follicle(s) enlarge in response to the letrozole stimulation 1, 2.

  • Cervical mucus production indicates rising estrogen from maturing follicles—letrozole does not deplete estrogen receptors like clomiphene citrate, so normal cervical mucus production is preserved and actually indicates successful ovarian response 1.

  • Light spotting at this point in your cycle may represent either mid-cycle estrogen breakthrough bleeding as follicles mature, or early luteinizing hormone (LH) surge-related changes 3.

What These Hormone Changes Mean

  • The FSH rise to 12.2 IU/L on day 7 occurred because letrozole blocks estrogen production, removing negative feedback on your pituitary gland 1.

  • The subsequent drop to 2.4 IU/L on day 9 indicates your follicles are now producing estrogen (despite letrozole), which restores negative feedback—this is the desired effect and suggests you have responsive follicle(s) developing 1, 4.

  • This FSH pattern promotes mono- or oligo-ovulation rather than excessive multifollicular development, because estrogen receptors in your brain remain functional with letrozole (unlike with clomiphene) 1.

What You Should Do Now

Continue your current course and monitor for ovulation:

  • No intervention is needed for these symptoms—they indicate appropriate ovarian response 1, 2.

  • Begin monitoring for LH surge starting now (cycle day 9-10), as ovulation typically occurs 12-14 days after starting letrozole at your dose 4, 5.

  • Expect ovulation around cycle days 12-14 based on the typical timeline with 7.5 mg letrozole 2, 4, 5.

  • The cervical mucus you're experiencing is favorable for conception and should not be suppressed—this is an advantage of letrozole over clomiphene 1.

When to Seek Urgent Evaluation

Contact your provider immediately if you develop:

  • Severe abdominal pain or distension (could indicate ovarian hyperstimulation syndrome, though rare with letrozole) 6.

  • Heavy vaginal bleeding (more than light spotting) 3.

  • Positive pregnancy test with worsening pain (to rule out ectopic pregnancy if you conceived in a prior cycle) 3.

Important Context About Your Letrozole Dose

  • Your 7.5 mg dose is higher than standard but is supported by evidence showing increased follicular development and pregnancy rates compared to lower doses 2, 4.

  • Studies show 7.5 mg produces more mature follicles than 2.5 mg without detrimental effects on endometrial thickness 2, 4.

  • However, 7.5 mg does not show clear advantage over 5 mg in head-to-head comparisons for ovulation or pregnancy rates 5.

  • Your endometrial thickness should be monitored as letrozole combined with gonadotropins (if used) can thin the endometrium, though this is less concerning with letrozole alone 7.

Expected Timeline Going Forward

  • Ovulation should occur within 3-5 days (cycle days 12-14) based on your current symptoms and hormone pattern 4, 5.

  • Plan intercourse or insemination when LH surge is detected or when your largest follicle reaches 18 mm on ultrasound 4, 5, 7.

  • The spotting should resolve within 24-48 hours as you approach ovulation 3.

Related Questions

What is the cause of vaginal bleeding on day 14 in a female of reproductive age undergoing fertility treatment with letrozole (5mg) from day 3 to day 7?
Can letrozole (aromatase inhibitor) cause a false‑positive urine luteinizing hormone (LH) ovulation test in women undergoing ovulation induction?
What is the reason to increase the letrozole (Femara) dose when using it for ovulation induction?
Is the bleeding that occurred on day 16 onwards after letrozole (aromatase inhibitor) induction, ovulation on day 12, and spotting on day 14, a withdrawal bleed or a typical menstrual period in a patient undergoing fertility treatment?
Can a woman undergoing multiple cycles of letrozole (aromatase inhibitor) therapy for infertility develop early menopause?
What are the normal follicle‑stimulating hormone (FSH) levels on cycle days 5, 7, and 9 for a reproductive‑age woman taking letrozole 7.5 mg daily from cycle day 3 to 7?
What is the muscle‑relaxant of choice for a patient with Parkinson disease who is already receiving levodopa and amantadine?
What is ventricular heart disease, including its types, etiologies, clinical presentation, diagnostic evaluation, and management recommendations, as described in Harrison's Principles of Internal Medicine?
When should I expect the luteinizing hormone (LH) surge after cycle day 9 in my letrozole ovulation induction cycle?
In an adult (≥18 years) with episodic migraine (≥4 migraine days/month) or chronic migraine (≥15 headache days/month, ≥8 migraine days) who has failed at least two approved preventive therapies, what are the indications and criteria for prescribing Ajovy (fremanezumab) for migraine prophylaxis?
What pacemaker mode should be programmed for a pacing‑dependent patient before an elective surgery that will use monopolar electrocautery near the heart?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.